Recombinant activated factor VII: 30 years of research and innovation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hedner, 2007, Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent, Neuroradiology, 49, 789, 10.1007/s00234-007-0240-2
Ahlberg, 1965, Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B, Acta Orthop Scand Suppl, Suppl. 77, 3, 10.3109/ort.1965.36.suppl-77.01
Nilsson, 1970, Our experience in Sweden with prophylaxis on haemophilia, Bibl Haematol, 34, 111
DiMichele, 2007, International workshop on immune tolerance induction: consensus recommendations, Haemophilia, 13, 1, 10.1111/j.1365-2516.2007.01497.x
Nilsson, 1973, Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide, Ann Intern Med, 78, 91, 10.7326/0003-4819-78-1-91
Fekete LF, Holst SL, Peetoom F, De Veber LL. “Auto” factor IX concentrate: a new therapeutic approach to treatment of hemophilia A patients with inhibitors. 1972.
Lusher, 1980, Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial, N Engl J Med, 303, 421, 10.1056/NEJM198008213030803
Sjamsoedin, 1981, The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial, N Engl J Med, 305, 717, 10.1056/NEJM198109243051301
Young, 2008, Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison, Haemophilia, 14, 287, 10.1111/j.1365-2516.2007.01601.x
Blatt, 1974, Thrombogenic materials in prothrombin complex concentrates, Ann Intern Med, 81, 766, 10.7326/0003-4819-81-6-766
Davey, 1976, Acute coagulopathy following infusion of prothrombin complex concentrate, Am J Med, 60, 719, 10.1016/0002-9343(76)90509-X
Edson, 1972, Letter: Prothrombin-complex concentrates and thrombosis, N Engl J Med, 290, 403
Kasper, 1973, Postoperative thromboses in hemophilia B, N Engl J Med, 289, 160, 10.1056/NEJM197307192890320
Kasper, 1975, Thromboembolic complications, Thromb Diath Haemorrh, 33, 640
Kingdon, 1975, Potentially thrombogenic materials in factor IX concentrates, Thromb Diath Haemorrh, 33, 617
Marchesi, 1974, Letter: Prothrombin-complex concentrates and thrombosis, N Engl J Med, 490, 403
Steinberg, 1973, Vascular lesions in hemophilia B, N Engl J Med, 289, 592, 10.1056/NEJM197309132891118
Hilgartner, 1983, The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors, Blood, 61, 36, 10.1182/blood.V61.1.36.36
Kasper, 1976, Letter: Rising factor VIII inhibitor titers after Konyne factor IX complex, N Engl J Med, 295, 505, 10.1056/NEJM197608262950916
Stenbjerg, 1978, Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII, Acta Med Scand, 203, 471, 10.1111/j.0954-6820.1978.tb14910.x
Blajchman, 2006, The continuing risk of transfusion-transmitted infections, N Engl J Med, 355, 1303, 10.1056/NEJMp068178
Dolan, 2006, Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience, Haemophilia, 12, 16, 10.1111/j.1365-2516.2006.01196.x
Ironside, 2006, Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies, Haemophilia, 12, 8, 10.1111/j.1365-2516.2006.01195.x
Pipe, 2006, The physician's role in selecting a factor replacement therapy, Haemophilia, 12, 21, 10.1111/j.1365-2516.2006.01197.x
Tapper, 2006, Emerging viral diseases and infectious disease risks, Haemophilia, 12, 3, 10.1111/j.1365-2516.2006.01194.x
Hedner, 1976, Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo, Thromb Haemost, 35, 386, 10.1055/s-0038-1647933
Hedner, 1979, Studies on the thrombogenic activities in two prothrombin complex concentrates, Thromb Haemost, 42, 1022, 10.1055/s-0038-1656993
Hedner, 1983, Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors, J Clin Invest, 71, 1836, 10.1172/JCI110939
Hedner, 1989, Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high titer inhibitors, Haemostasis, 19, 335
Hagen, 1986, Characterization of a cDNA coding for human factor VII, Proc Natl Acad Sci U S A, 83, 2412, 10.1073/pnas.83.8.2412
Jurlander, 2001, Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development, Semin Thromb Hemost, 27, 373, 10.1055/s-2001-16890
Bjoern, 1986, Activation of coagulation factor VII to VIIa, Research Disclosure, 269, 564
Bjoern, 1991, Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine, J Biol Chem, 266, 11051, 10.1016/S0021-9258(18)99126-X
Klausen, 1998, Analysis of the site-specific asparagine-linked glycosylation of recombinant human coagulation factor VIIa by glycosidase digestions, liquid chromatography, and mass spectrometry, Mol Biotechnol, 9, 195, 10.1007/BF02915793
Thim, 1988, Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells, Biochemistry, 27, 7785, 10.1021/bi00420a030
Brinkhous, 1989, Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease, Proc Natl Acad Sci U S A, 86, 1382, 10.1073/pnas.86.4.1382
Diness, 1990, Effect of recombinant human FVIIA on warfarin-induced bleeding in rats, Thromb Res, 59, 921, 10.1016/0049-3848(90)90116-T
Diness, 1992, Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model, Thromb Res, 67, 233, 10.1016/0049-3848(92)90142-W
Erhardtsen, 2000, Pharmacokinetics of recombinant activated factor VII (rFVIIa), Semin Thromb Hemost, 26, 385, 10.1055/s-2000-8457
Hedner, 1988, Pharmacokinetics of rFVIIa in children, Haemostasis, 4
Lindley, 1994, Pharmacokinetics and pharmacodynamics of recombinant factor VIIa, Clin Pharmacol Ther, 55, 638, 10.1038/clpt.1994.80
Hedner, 1988, Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy, Lancet, 2, 1193, 10.1016/S0140-6736(88)90259-0
Macik, 1989, Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor, Am J Hematol, 32, 232, 10.1002/ajh.2830320315
Hedner, 1990, Factor VIIa in the treatment of haemophilia, Blood Coagul Fibrinolysis, 1, 307, 10.1097/00001721-199008000-00009
Hedner, 1987, Comparison of the effect of factor VII preparted from human plasma (pVIIa) and recombinant VIIa (rVIIa) in vitro and in rabbits, Transfusion, 58, 270
Telgt, 1989, Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor, Thromb Res, 56, 603, 10.1016/0049-3848(89)90268-5
Rao, 1990, Factor VIIa-catalyzed activation of factor X independent of tissue factor: its possible significance for control of hemophilic bleeding by infused factor VIIa, Blood, 75, 1069, 10.1182/blood.V75.5.1069.1069
Monroe, 1994, Platelet procoagulant complex assembly in a tissue factor-initiated system, Br J Haematol, 88, 364, 10.1111/j.1365-2141.1994.tb05032.x
Monroe, 1997, Platelet activity of high-dose factor VIIa is independent of tissue factor, Br J Haematol, 99, 542, 10.1046/j.1365-2141.1997.4463256.x
Monroe, 2002, Platelets and thrombin generation, Arterioscler Thromb Vasc Biol, 22, 1381, 10.1161/01.ATV.0000031340.68494.34
Blombäck, 1996, Fibrinogen and fibrin–proteins with complex roles in hemostasis and thrombosis, Thromb Res, 83, 1, 10.1016/0049-3848(96)00111-9
Hedner, 2008, Factor VIIa and its potential therapeutic use in bleeding-associated pathologies, Thromb Haemost, 100, 557, 10.1160/TH08-07-0434
Allen, 2004, Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system, J Thromb Haemost, 2, 402, 10.1111/j.1538-7933.2003.00617.x
He, 2003, The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX, J Thromb Haemost, 1, 1215, 10.1046/j.1538-7836.2003.00242.x
Augustsson, 2014, In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia, Blood, 124, 3172, 10.1182/blood-2014-05-576892
Feng, 2014, FVIIa as used pharmacologically is not TF dependent in hemophilia B mice, Blood, 123, 1764, 10.1182/blood-2013-08-522987
Konkle, 2007, Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors, J Thromb Haemost, 5, 1904, 10.1111/j.1538-7836.2007.02663.x
Clark, 2012, Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa, J Thromb Haemost, 10, 2383, 10.1111/j.1538-7836.2012.04917.x
Gopalakrishnan, 2010, Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa), J Thromb Haemost, 8, 301, 10.1111/j.1538-7836.2009.03696.x
Gopalakrishnan, 2010, rFVIIa transported from the blood stream into tissues is functionally active, J Thromb Haemost, 8, 2318, 10.1111/j.1538-7836.2010.04010.x
Zatta, 2015, The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII, Blood Transfus, 13, 86
Kenet, 1999, Treatment of traumatic bleeding with recombinant factor VIIa, Lancet, 354, 1879, 10.1016/S0140-6736(99)05155-7
Mohr, 2005, Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma, Crit Care, 9, S37, 10.1186/cc3784
Rossaint, 2010, Management of bleeding following major trauma: an updated European guideline, Crit Care, 14, R52, 10.1186/cc8943
Vincent, 2006, Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective, Crit Care, 10, R120, 10.1186/cc5026
Boffard, 2005, Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials, J Trauma, 59, 8, 10.1097/01.TA.0000171453.37949.B7
Mayer, 2005, Recombinant activated factor VII for acute intracerebral hemorrhage, N Engl J Med, 352, 777, 10.1056/NEJMoa042991
Mayer, 2008, Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage, N Engl J Med, 358, 2127, 10.1056/NEJMoa0707534
Villar, 2004, Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A, Haemophilia, 10, 352, 10.1111/j.1365-2516.2004.00925.x
Kavakli, 2006, Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multicentre, randomised, double-blind, cross-over trial, Thromb Haemost, 95, 600, 10.1160/TH05-07-0510
Kjalke, 2001, High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system, Br J Haematol, 114, 114, 10.1046/j.1365-2141.2001.02870.x
Poon, 1999, Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia, Blood, 94, 3951, 10.1182/blood.V94.11.3951
Tengborn, 1996, A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa, Thromb Haemost, 75, 981
Poon, 2004, Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey, J Thromb Haemost, 2, 1096, 10.1111/j.1538-7836.2004.00767.x
Poon, 2007, Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia, Vasc Health Risk Manag, 3, 655
Brenner, 2007, Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency, Hematology, 12, 55, 10.1080/10245330601111573